Oct 16 (Reuters) - Shah Capital, one of Novavax's top shareholders, said on Friday it no longer seeks to influence control of the vaccine maker after restructuring into a family office. • The investor ...

What Happened? A number of stocks fell in the afternoon session after capital-intensive growth equities experienced sharp ...

Vaccine stocks are cracking under intense selling pressure, and one small developer with no control over its own commercial ...

Sanofi just handed Novavax a commercial lifeline for the fall vaccination season, and the stock is reacting in a way that ...

Novavax has delivered a sharp mix of gains and losses over the years, and the recent rebound puts fresh attention on a basic ...

In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.

Novavax jumped on plague fears, but weak finances and no clear drug path remain. Click here to read this latest analysis of ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...

Bank of America raised its Novavax target from USD 7.00 to USD 8.00 on October 9, 2026, but kept an Underperform rating. As ...

Novavax (NVAX) stock surged 16% after Sanofi’s combination vaccine trial cleared key European approvals, triggering a ...

Novavax, Moderna and other vaccine stocks rallied after a lab worker in Russia died following suspected plague exposure, WHO ...

(Reuters) -Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no ...